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Stlmmary 
The gene responsible for X-linked agammaglobulinemia (XLA) has been recently identified to 
code for a cytoplasmic tyrosine kinase (Bruton's  agammaglobulinemia tyrosine kinase, BTK), 
required for normal B cell development.  BTK, like many other cytoplasmic tyrosine kinases, 
contains  Src homology domains  (SH2 and SH3),  and catalytic kinase domain. SH3 domains 
are important for the targeting of signaling molecules to specific subcellular locations. We have 
identified a family with XLA whose affected members have a point mutation (g ~  a) at the 
5' splice site of intron 8, resulting in the skipping of coding exon 8 and loss of 21 amino acids 
forming the COOH-terminal portion of the BTK SH3 domain. The study of three generations 
within this kinship, using restriction fragment length polymorphism and DNA analysis, allowed 
identification  of the mutant X chromosome responsible for XLA and the carrier status in this 
family.  BTK  mRNA  was  present  in  normal  amounts  in  Epstein-Barr  virus-induced  B 
lymphoblastoid cell lines established from affected family members. Although the SH3 deletion 
did not alter BTK protein stability and kinase activity of the truncated BTK protein was normal, 
the affected patients nevertheless have a severe B cell defect characteristic for XLA. The mutant 
protein was modeled using the normal BTK SH3 domain. The deletion results in loss of two 
COOH-terminal ~ strands containing several residues critical for the formation of the putative 
SH3 ligand-binding pocket. We predict that, as a result, one or more crucial SH3 binding proteins 
fail to interact with BTK, interrupting the cytoplasmic signal transduction process required for 
B cell differentiation. 
X 
-linked  agammaglobulinemia (XLA) 1,  first described 
by Bruton in 1952 (I), is characterized by markedly re- 
duced or absent serum immunoglobulins of all isotypes and 
failure to  produce antigen-specific  antibodies  (2,  3).  The 
number of circulating B lymphocytes is drastically diminished, 
and germinal centers are absent in lymph nodes. X-chromo- 
some inactivation studies have suggested that the gene defect 
1 Abbreviations  used in this paper: B-LCL,  B lymphoblastoid  cell line; BTK, 
Bruton's agammaglobulinemia tyrosine kinase; Kv,  K  value (rate of 
bacteriophage inactivation); PH,  pleckstrin  homology;  Pl-3  kinase, 
phosphatidylinositol-3'  kinase; RT, reverse transcriptase; SH, Src homology 
domain; TH, Tec homology; xid, X-linked immunodeficiency; XLA, 
X-linked agammaglobulinemia. 
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is intrinsic  to the B cell lineage (3). The gene responsible 
for XLA, mapped by family studies to the long arm of the 
X chromosome at Xq22 (4), has recently been identified to 
be a cytoplasmic tyrosine kinase (Bruton's  agammaglobu- 
linemia tyrosine kinase, BTK) (5-7). The enzyme, BTK, is 
expressed in most hematopoietic cells, but is selectively  down- 
regulated in plasma cells and T lymphocytes (5, 6, 8, 9) and 
appears to play a critical role in the regulation of B cell prolifer- 
ation and differentiation.  Like most other cytoplasmic tyro- 
sine kinases, BTK contains SH2 and SH3 regions (Src ho- 
mology domains), and a catalytic kinase domain (10). Unlike 
Src  subfamily  cytoplasmic  tyrosine kinases, BTK lacks  a 
COOH-terminal regulatory tyrosine and an NH2-terminal 
myristylation signal. A recently identified novel domain, the 
pleckstrin homology (PH) domain present in many signaling 
proteins, is also found in the NH2-terminal region of BTK 
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60-80 amino acid segment located between the PH and SH3 
domains, tentatively designated the Tec homology (TH) do- 
main (9), have suggested BTK and several other homologous, 
lineage-restricted tyrosine kinases are members of a different 
kinase subfamily (5,  9,  11). 
The initial reports implicating BTK in XLA demonstrated 
loss of BTK kinase activity (5) or point mutations resulting 
in single amino acid substitutions within the kinase (SH1) 
domain (6). Pre B and B cell lines established from XLA pa- 
tients were found to have reduced or absent BTK mRNA, 
BTK protein expression, and kinase activity (5). Subsequently, 
additional substitutions and stop codon formation have been 
reported in this domain (12,  13). 
These studies demonstrated a critical role for BTK in early 
B cell development. Identification of mutations within other 
BTK functional domains, however, is likely to lead to addi- 
tional insights into the BTK signaling pathways. Two such 
informative mutations have recently been described, both in 
the PH and in the SH2 domains. A point mutation within 
the Btk PH region affecting residue 28 (Arg -~ Cys) results 
in a moderately severe X-linked immunodeficiency (xid) in 
the mouse (14, 15), whereas severe XLA was found in a family 
with four affected brothers having the same residue mutated 
to His (13). This mutation alters a highly conserved residue 
within the (PH) domain of BTK (9, 11, 16). Unlike the R28H 
mutation in the XLA patients, the K28C mutation in the 
xid mouse affects  B cell signaling without blocking pre-B 
cell clonal expansion.  Mutations in the SH2 domain were 
found in both "atypical"  and "classical" (severely affected) 
XLA patients (12,  13,  17).  These mutations altered highly 
conserved residues (K288W; K307G; Y361C) important in 
forming the SH2 phosphotyrosine binding pocket. The mu- 
tant ]KI'K protein (Y361C) isolated from a B cell line estab- 
lished from a patient with atypical XLA had decreased sta- 
bility predicted to result from the alteration in SH2 binding 
function (17). 
In the present study, we report a point mutation at a donor 
splice junction, resulting in exon skipping and loss of 21 amino 
acids forming the COOH-terminal portion of the BTK SH3 
domain. The SH3  domain is  a  small (60-80  amino acid) 
module present in a large number of proteins involved in signal 
transduction and membrane cytoskeletal interactions.  The 
function of the SH3 domain is unknown, but it binds to 
peptides rich in proline and hydrophobic residues (18-20). 
The structure has been determined for five SH3 domains: 
Src (21), F3m (22), spectrin (23), p85 of phosphatidylinositol-Y 
kinase (PI-3 kinase) (24, 25), and PLC~/(26). These all share 
the same structural scaffolding where insertions and deletions 
appear on loops connecting adjacent ~/-strands.  The putative 
binding site lies on one face of the domain and is predicted 
to be significantly altered by this ddetion (23). Despite the 
ddetion,  the truncated BTK protein is stable and remains 
functionally active. However, the ddetion results in the XLA 
phenotype in two affected males, suggesting that the SH3 
domain is likely to play a critical role in BTK-dependent sig- 
naling and normal B cell development. To our knowledge, 
this is  the first  naturally occurring mutation within,  and 
limited to,  an SH3 domains resulting in a human genetic 
disease. 
Materials and Methods 
XLA Family.  The members of a large family with an affected 
unde/nephew pair are shown in Fig. 1. Patient III-10 is a 41-yr-old 
male who had recurrent bacterial infections  since early infancy, 
resulting in chronic otitis media, chronic sinusitis, and bronchiec- 
tails. Before treatment with Ig was initiated, he had severe arthritis 
involving multiple  joints; serum lgG concentration was 135 mg/dl; 
IgA and IgM were not detectable. When immunized with bacte- 
riophage ~X174 (27), he had prolonged circulation of phage and 
failed to produce phage neutralizing antibody. His peripheral blood 
B lymphocyte proportion has been consistently <0.1%. A rectal 
biopsy showed absence of plasma cells. His nephew (IV-8) is an 
11-yr-old boy who at 6 mo of age, when the diagnosis was estab- 
1  2~  3  4~5~ 
III  A 
IV 
B  DXS 366  2  2  2  2 
DXS 442  2  2  1  2 
DXS 178  2  1  1  1 
s215 265  ~  2  2  2 
Sp  282  1  2  2  2 
DXS 94  2  1  1  1 
Figure  1.  Pedigree  of a family with 
XLA. The two affected males (IIl-10 
and IV-8)  are indicated by solid symbols 
(I). Carrier females,  as determined  by 
KT-PCR and by amplification muta- 
genesis,  are  identified  by  half-ftlled 
symbols  (O);  (|  indicate  female 
members  at  risk  studied  in  similar 
fashion and found to be nonaffeeted. 
Symbols A, 13, C, and D indicate haplo- 
types as defaned  by KPLP and markers 
linked to the BTK locus; these markers 
are described in detail in the text. The 
alldes at each locus are indicated with 
a 1 for the smaller and a 2 for the larger 
allde. The genotype for individual Ib2 
is deduced. 
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(IVIG) was initiated, had a serum IgG level of 267 mg/dl;  IgA 
and IgM were no demonstrable. He had <1% B cells. When im- 
munized with bacteriophage, patient IV-8 cleared antigen within 
1 wk and showed a low but definite antibody response (patient's 
peak K-value [Kv, rate of bacteriophage inactivation] post primary 
immunization was 0.029 [normal Kv = 50.1; 95% confidence  in- 
terval, 3.2-807]; patient's peak Kv post secondary immunization 
was 0.43 [normal Kv = 362; 95% confidence  interval, 119-1037]). 
All of this antibody was of the IgM class. He responded well to 
IVIG therapy and is presently asymptomatic and without chronic 
disease. The mothers (II-1 and III-8) of the two patients are healthy. 
II-1 had four healthy brothers, two still alive, and two sisters who 
have between them four healthy boys. 
Cells and Cell Lines.  PBMC were separated from heparinized 
venous blood by centrifugation over lymphocyte  separation  medium 
(Ficoll-Paque; Pharmacia  LKR Uppsala, Sweden). EBV-transformed 
B lymphoblastoid cell lines (B-LCL)  were derived from PBMC in- 
fected with supernatants from the marmoset cell line B95.8 (28). 
B-LCL were established from both patients (III-10, IV-8) and from 
the obligate carriers (II-1, III-8). 
DNA  Purification, Southern Analysis, and  RFLP.  Genomic 
DNA was extracted from leukocytes of 5 ml whole blood (anti- 
coagulated with EDTA) and purified using a method described 
in the Quiagen Genomic Handbook (provided by Quiagen Inc., 
Chatsworth,  CA). 
Purified gen0mic DNA from the XLA patients and normal con- 
trols was digested overnight separately with restriction enzymes 
EcoRI, HindIII, and TaqI. The digested DNA samples were sub- 
jected to agarose (0.8%) gel electrophoresis and the DNA frag- 
ments were transferred from the gel to a nylon membrane, fol- 
lowed by hybridization with a 32p-labeled BTK full-length cDNA 
probe 14-6 (6). 
Markers used to analyze the inheritance pattern of alleles in the 
region of q21.3-q22 on the X chromosome included probes for 
DXS366, DXS442, and DXS265 (gift of  Dr. David Barker, Univer- 
sity of Utah, Salt Lake City, UT) (29), DXS3 (gift of Dr. Gail 
Bruns, Boston Children's Hospital, Boston, MA) (30), SP282 (31); 
DXS94 (32) and DXS178 (33) were obtained from American Type 
Culture Collection (Rockville, MD). DNA, prepared from EDTA 
blood collected  from selected  family  members (Fig. 1), was digested 
to completion with the appropriate restriction enzyme for each 
marker (TaqI for DXS366, DXS3, and DXS178, MspI for DXS442 
and DXS265, BstNI for SP282, and PstI for DXS94) and Southern 
blotted for hybridization to the appropriate probes as previously 
described (34). 
PCR and Sequencing of  Genomic DNA.  Purified  genomic DNA 
samples, prepared from controls and members of the XLA family, 
were amplified  with two amplification  primers, 5'-CAGGAAGGC- 
TACATTCCT-Y and 5'-CTCCGAGTCATGTGTTTGA-3',  which 
span the suspected mutation site and whose selection was based 
on the published eDNA sequence (6); the former primer cor- 
responded to nucleotides 910-927, the latter was complementary 
to nucleotides  998-979 of the eDNA sequence. The following  PCR 
conditions were used: 5 rain at 94~  followed  by 30 cycles  at 94~ 
for 1 min, 55~  for 1 rain, and 72~  for 1 min. The resulting 
PCR products were "~1,300 bp in length.  The amplified DNA 
fragments were separated by agarose gel electrophoresis and elec- 
troelution. Direct sequencing  was performed by the dideoxynucleo- 
tide chain termination method (35), using the sequenase DNA se- 
quencing kit (United States Biochemical  Corp., Cleveland, OH). 
Amplification Mutagenesis.  Amplification  mutagenesis  is a PCR 
method designed  to detect genomic mutations by directly screening 
DNA fragments. A new restriction enzyme site is created by in- 
troducing  (or changing) one nucleotide near the 3' end of an 
amplification  primer. After regular amplification, the new site can 
be recognized (either the normal or the mutant sequence but not 
both) by a designated enzyme (36). The set of  primers we designed 
for the amplification mutagenesis to detect the mutation were the 
"sense"  primer 5'-TG~~C'rGGAGGC-3'  and the "anti- 
sense" primer, 5~  which 
served as mutagenesis  primer having one base substitution (G_); this 
created a new restriction enzyme RsaI site for the amplified  DNA. 
The resulting DNA fragment consisted  of 149 bp. After RsaI diges- 
tion, the fragments were electrophoresed in a 2% Metaphor TM 
agarose gel (FMC Bioproducts, Rockland, ME) and the DNA bands 
were made visible with ethidium bromide staining. 
RNA Isolation  and Northern Blot Analysis.  Total  RNA was iso- 
lated from PBMC or B-LCL obtained from normal controls and 
from members of the XLA family, using a single step method and 
Trizol  TM (GIBCO BRL, Gaitbersburg, MD) (37). Approximately 
10/~g of total RNA was electrophoresed  on a formaldehyde-agarose 
gel, transferred to nylon membrane and hybridized with a 32p_ 
labeled BTK cDNA clone 14-6 (6), as previously described (38). 
Reverse  Transc@tase (RT)-PCR  and  Sequencing.  First-strand 
cDNA was prepared from RNA isolated from PBMC or B-LCL 
obtained from normal controls and members of the XLA family. 
2.5/~g of total RNA was incubated  with oligo (dT) as primer using 
the SuperScrip Preamplification  System  kit (GIBCO BRL) as recom- 
mended  by the manufacturer.  PCR was performed using a modified 
method described by Saiki et al. (39) with an automatic DNA 
thermal cycler (Coy Laboratory Products Inc., Ann Arbor, MI). 
The PCR reactions underwent 35 cycles  at 94~  for 2 rain, 60~ 
for 1.5 rain, 72~  for 2 rain, and a final extension step at 72~ 
for 10 min. Overlapping  primer pairs were selected  from the known 
BTK cDNA  sequence to  cover the entire  coding region.  The 
amplified  DNA fragments were isolated by agarose  gel electropho- 
resis; the bands were made visible with ethidium bromide and in 
selected cases electroeluted. Direct sequencing of the eluted mate- 
rial was performed using a modified dideoxynucleotide chain ter- 
mination  method  (40) and  the  PFU  DNA  sequencing kit 
(Stratagene, La Jolla, CA). 
BTK Protein Analysis.  To measure BTK protein synthesis, 107 
EBV transformed B lymphoblasts were incubated for 4 h with 250 
#Ci [3SS]methionine/ml  in methionine-frec medium. The labeled 
protein was immunoprecipitated with anti-BTK antibody, as de- 
scribed previously (5). Immunoprecipitates were electrophoresed 
by SDS-page and visualized by autoradiography. To determine au- 
tokinase activity, BTK was immunoprecipitated  with anti-BTK an- 
tibody from lysates  of  patient and normal B lymphoblasts, and ac- 
tivity assayed  by addition of 3,-[32p]ATP in 20 mM PIPES (pH 7.0) 
containing 20 mM MnC1 (5). Samples were run on SDS-page and 
visualized  by autoradiography. To determine transphosphorylation 
of exogenous substrate, immunoprecipitated  BTK from normal and 
patient  B-LCL lysates was  incubated in  the presence of acid- 
denatured enolase and 3,-[32p]ATP (5). 
Computational Techniques.  The BTK SH3 sequence was com- 
pared with those of SH3s for which three-dimensional structures 
have been determined and were available, including Fyn, spectrin, 
and p85 ofPI-3 kinase. The BTK SH3 structure was modeled with 
InsightII (Biosym Technologies, Inc., San Diego, CA) and refined 
by energy  minimization  with  the  program  CHARMM (41). 
Minimization was performed stepwise  with adopted basis Newton- 
Raphson algorithm first relaxing hydrogen atoms. Then harmonic 
constraints were put on the conserved regions and the loops were 
minimized for 1,000 steps after which C~ atoms in the conserved 
463  Zhu et al. region were harmonically  constrained. The SH3 deletion was made 
by discarding the 14 COOH-terminal  residues (the other  seven 
deleted amino acids are in a loop joining SH3 and SH2 domains) 
from the SH3 model and performing the minimizations described 
above. 
Both the normal BTK SH3 and the deletion mutant were sub- 
jected to molecular dynamics at 300 K with the CHARMM pro- 
gram. The minimized structures were used in the simulation in 
vacuo. The parameters used in the energy function were standard 
CHARMM parameters. The molecular  dynamics  integrations were 
done using the time-step of 1 fs at a constant temperature of  300 K. 
The system  was slowly warmed to 300 K over the course of 8.5 ps. 
After the warming period, the simulation was continued for an 
additional 188.5 ps. The temperature was checked  every five time- 
steps and a~owed  to vary 10 K. The SHAKE routine (42) was used 
to constrain covalent bonds between hy&ogens and heavy  atoms. 
Results 
A  Splice Donor Mutation Results in Exon Loss of  BTK.  We 
performed Southern blot analyses of patient genomic DNA 
digested with restriction enzymes EcoRI, HindlII, and TaqI, 
and hybridized to the BTK probe 14-6. No major differences 
in restriction DNA fragment sizes were identified when those 
of the patients were compared with those of normals (results 
not shown). Direct sequencing of amplified genomic DNA 
fragments revealed  a g  --*  a point mutation involving the 
first nucleotide of a donor splice junction in both patients' 
BTK genes (Fig. 2 A). The mutation involves a critical nucleo- 
Figure  2.  PCIL-sequence  analysis  of genomic  DNA and cDNA of  BTK 
of the affected  males. (A) Location  of the g --* a point mutation  involving 
the first nucleotide  of a donor splice  junction at the 5' end of an intron. 
This mutation  alters the splice donor site 5'-gtaagt to ataagt, preventing 
the pairing and exon  joining  at the 3' site. (B)i3equenceanalysis  of  patient 
cDNA indicate  the deletion  of  63 nucleotides  between  nudeotide  908 and 
972. (C) The deletion of 63 base pairs coding for amino acid residues 
260-280, caused  by the g ---* a point mutation  involving  the first nucleo- 
tide of the donor splice  junction is indicated.  The deletion,  located  in the 
cDNA coding  for the COOH-terminal portion of the SH3 domain,  in- 
volves nucleotides 909-971. 
Figure  3.  Normal expression of 
BTK  mRNA  in B cells  from  the XLA 
patients, mRNA  was isohted  from  B- 
I.CLs  established  from  a normal  con- 
trol, a carrier female  (III-8), and an 
XLA patient  (IV-8). The mRNA ob- 
tained from the  XLA  patient is 
smaller than control mRNA. 
tide at  the 5'  end of an intron required for proper  splice 
function (43). 
Northern blot analysis of total RNA isolated from PBMC 
and B-LCLs of the two patients and the two obligate carrier 
females (II-1, III-8) demonstrated the presence of normal quan- 
tities of mRNA; Fig. 3 illustrates mRNA isolated from B-LCL 
of a normal control, a carrier female, and a patient. The pa- 
tient's mRNA appears slightly smaller than control mtLNA. 
BTK cDNA was generated and amplified by RT-PCR, 
using two overlapping primer pairs  that covered the entire 
coding region of  BTK. The PCtL amplified cDNA fragments 
spanning nucleotides 763-1294, derived from the cDNA of 
XLA patients III-10 and IV-8 (using primers GTCTCCACA- 
AGTGAGCTGAA  [sense] and  CAGTGGAAGGTGCAT- 
TCTTG [antisense]),  were shorter than those obtained from 
normal controls (Fig,  4 A). Sequencing of the PCR prod- 
ucts revealed that the patients' cDNA had a deletion of 63 
nucleotides including bp 909 and 971 (Fig. 2, B and C). To 
exclude a PCR artifact, we used two separate tLNA prepara- 
tions isolated from B-LCLs derived from each of the two pa- 
tients for RT-PCR and found the same deletion each time. 
Carrier Detection.  To  trace  the inheritance and possible 
origin  of the  affected  X  chromosome,  we  selected  seven 
markers  closely linked  to  the  region  of  the  Kirk locus 
(Xq21.3-Xq22)  to be used in RFLP analysis. The polymor- 
phisms at DXS3, DXS442, DXS178,  DXS265,  SP282,  and 
DXS94 indicated that individuals III-3, III-6, III-8, and III- 
10 had inherited from their mother (II-1) the same marker 
alleles (haplotype B in Fig. 1) linked to the BTK locus. This 
data identifies III-3 and III-6 as possible carriers,  since their 
brother III-10 is affected with XLA. Assuming that no cross- 
overs between the marker aUdes and BTK occurm:i, individual 
III-1 is not a carrier;  she inherited the same maternally de- 
rived allele (allele A in Fig. 1) as her normal brother III-5. 
Further analysis shows that individual IV-8 who was diag- 
nosed with XLA (and his obligate carrier mother Ili-8) also 
inherited the B haplotype associated with the defective BTK 
gene. 
To identify  accurately those females carrying the X-chromo- 
some with the point mutation located within the BTK gene, 
we developed a simple detection method using amplification 
mutagenesis and compared the results with those obtained 
by RT-PCR and electrophoresis. A DNA fragment of 149 bp 
was selected for amplification mutagenesis. When generated 
464  Deletion  within the Src Homology  Domain 3 of Bruton's Tyrosine  Kinase Figure 4.  Analysis of genomic DNA and eDNA 
from affected males, female members of the  XLA 
family, and  normal male and female controls. (A) 
BTK eDNA was generated  and amplified  by RT-PCR 
using primer pairs that amplified  a fragment spanning 
nucleotide 763 to 1294. The primers used were GTC- 
TCCACAAGTGAGCTGAA (sense) and CAGTGG- 
AAGGTGCATTCTTG  (antisense). The PCR product 
derived  from the eDNA of  both XLA patients (III-10 
and IV-8) were  shorter  than those  obtained  from normal 
controls (469  vs. 532 nucleotides).  PCR amplified  frag- 
ments derived  from eDNA of female  members of the 
XLA family using the same primer pair showed two 
patterns. Those females carrying the gene with the 
g --- a point mutation resulting in the loss of an exon 
have two bands of eDNA, one representing a eDNA 
fragment of normal size (532 nucleotides) and one 
shorter by 63 nucleotides (II-1, III-3, III-6, III-8, IV- 
3, IV-4, IV-5, IV-6). Those not carrying the abnormal 
gene show only a single band of normal size (III-1, 
IV-7).  (B)  Using  amplification mutagenesis  (see 
Materials and Methods) a DNA fragment of 149 bp 
was generated. The primers were selected to ensure 
that the fragment generated from genomic DNA of 
normal controls is cleaved  by restriction enzyme RsaI 
into two segments, one being 127 bp and the other (too small to stay on the gel) 22 bp. In contrast, DNA fragments with the g --- a mutation 
cannot be digested by P,.saI. The affected  males are identified by a DNA fragment size of 149 bp. The eight female carriers showed two bands, one 
normal (127 bp) and the other abnormal (149 bp). The results of the two techniques are in complete agreement. 
from genomic DNA of individuals with normal BTK, this 
fragment is cleaved by restriction enzyme RsaI into two seg- 
ments,  one being  127 bp and the other 22 bp;  the latter is 
too small to show up on the gel. However, DNA with the 
g --~ a mutation cannot be digested by RsaI. The DNA frag- 
ment size (Fig.  4 B) identifies the affected males who have 
a single band of 149 bp and the eight female carriers with 
two bands, one normal (127 bp) and one abnormal (149 bp). 
The results are in agreement with analysis of PCR amplified 
fragments spanning nudeotides 763-1294 derived from eDNA 
of female members  of the  XLA  family (Fig.  4  A). 
Mutant SH3 BTK Results in XLA  without Affecting Kinase 
Activity.  The amount of BTK protein synthesized by B lym- 
phoblasts  derived  from  patient  III-10  was  estimated  by 
[3SS]methionine metabolic pulse labeling. Protein expression 
was quantitatively similar to that of control B lymphoblasts 
(Fig.  5 A).  This  is consistent  with  the normal  expression 
of BTK mRNA  shown in Fig. 3 and suggests that the SH3 
deletion does not significantly alter the BTK protein stability. 
As predicted by sequence analysis, the BTK protein product 
of the patient's B-LCL was truncated.  To assess  the function 
of the altered BTK, we measured phosphorylation activity 
in  vitro.  Both  autophosphorylation  (Fig.  5  B)  and  trans- 
phosphorylation  of the exogenous substrate,  enolase,  (Fig. 
5  C) by the mutant  BTK was  equivalent to control BTK, 
indicating that functional kinase activity of the truncated BTK 
is normal. 
Structure of  the BTK SH3 Domain.  The BTK SH3 sequence 
was compared with those of Fyn, spectrin, and p85 of PI-3 
kinase, for which structural coordinates were available. The 
Figure 5.  Expression  of  BTK by B lymphoblasts  from an affected  male 
and a normal control. (A) B lymphoblasts were incubated with [3sS]me- 
thionine in methionine-free  medium. BTK was immunoprecipitated  with 
anti-BTK  antibody, electrophoresed  by SDS-PAGE, and autoradiographed. 
BTK protein expression  by B lymphoblasts  from patient III-10 was similar 
to that of  control B lymphoblasts  (horizontal  line), but the size was smaller 
(~), reflecting the deletion of 21 amino acids. Incorporation of metabolic 
label, measured by TCA precipitabh counts, was 40% lower in the mu- 
tant B lymphoblasts and accounts for the reduction in signal in the patient 
lane  (B)  BTK  function  as  measured by  autophosphorylation using 
[32P]ATP was similar in the patient and in the control; the patient BTK 
was truncated. (C) Transphosphorylation  of exogenous  substrate (Asterisk, 
enolase) was similar in the immunoprecipitated BTK from patient and 
control B lymphoblasts. 
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 Src family member Fyn was found to have the greatest iden- 
tity, 45% (Fig. 6 A), and was thus used as the template for 
modeling. There was only a single deletion of one residue 
on a short loop connecting two/3 strands. Most of the amino 
acid substitutions were by physicochemically  related ones, and 
the sequences were very related facilitating reliable modeling. 
The structure of the normal BTK SH3 consists presum- 
ably of two antiparallel/3-sheets  (Fig. 6) and is very similar 
to Fyn and Src both at the sequence and structural level. The 
single amino acid deletion in wild type BTK (as compared 
with wild-type Fyn) did not change the fold. This loop is 
known to have the largest deviations in Fyn when compared 
with other SH3s (21). The central hydrophobic core is con- 
served also in BTK; of the six residues in Fyn, four are iden- 
tical in BTK,  and one (F109 in Fyn) is replaced by another 
aromatic residue. SH3 of Fyn and Lyn were recently shown 
to bind to a proline-rich  region within the 85-kD subunit 
(p85) of PI-3 kinase, leading to a five- to sevenfold increase 
in the specific  activity ofPI-3 kinase (20). The ligand binding 
of Src has been studied with short proline-rich peptides (21). 
Many of the Src residues perturbed by ligand binding are ei- 
ther identical or substituted by related amino acids in BTK 
(Fig. 6 A). 
The SH3 deletion mutant was modeled from the normal 
BTK SH3. This structure is missing the 14 COOH-terminal 
residues including the two COOH-terminal/3 strands and 
the helix (Fig. 6). Thus the deletion mutant is lacking most 
of the residues forming the putative ligand binding region 
and missing essential parts of both the/3-sheets (Fig. 6 B). 
When substantial parts of a protein are missing, its confor- 
mation could be drastically altered. To analyze if this were 
the case in the BTK SH3 deletion mutant, the conformation 
was studied with modeling and molecular dynamics. The mu- 
tant was found to have a stable structure, although some- 
what different from the fold of corresponding section in the 
normal SH3.  The backbone atoms did not fluctuate more 
than in globular proteins in general, with a root mean square 
fluctuation of 0.64 ,~  during the last 120 ps of simulation, 
indicating stable structure. The organization of the secondary 
structural elements are shown in Fig. 6 B. The flexible NH2 
and COOH termini are separated by 12-15 A, while in the 
wild type BTK SH3,  the calculated distance is  13-14 A. 
Discussion 
The recent identification of the gene responsible for XLA 
allowed us to study the genetic defect and its effect on the 
function of BTK in a large family with two affected males. 
Both patients  were found to have demonstrable B cells in 
the peripheral blood that could be immortalized by EBV, and 
one patient (IV-8) was able to dear bacteriophage and to pro- 
duce a small amount of antibody (<1% of normal). These 
findings suggest a milder variant of the disease (44) although 
both patients  fulfill the criteria for XLA. 
The abnormality of the BTK gene responsible for the XLA 
phenotype in this family is a g ~  a point mutation at the 
5' end of intron 8 (intron assignment  is based on our un- 
published  data).  This mutation alters the splice donor site 
467  Zhu et al. 
5'-gtaagt  to ataagt. The first critical step during RNA pro- 
cessing is pairing of the 5'  splice site consensus sequence 
(5'-gtaagt)  with the complementary sequence on the small 
nucleoribonuclear protein,  U1 snRNA, within the spliceo- 
some (43). The g ~  a mutation at the 5' splice site ofintron 
8 alters an invariant nucleotide in the consensus sequence, 
preventing  the pairing and exon joining at the 3' site (45) 
and thus causes the skipping  of coding exon 8,  the most 
COOH-terminal of the exons forming the BTK SH3 do- 
main. In a recent review of 29 missense mutations involving 
the invariant g nucleotide at the 5' splice sites of  genes causing 
various human diseases, 11 mutations were identified whose 
only consequence was skipping of an exon (46). In the re- 
maining mutations, exon skipping was associated with alter- 
native splicing at nearby sites. In the XLA patients described 
here, coding exon 8 was skipped, causing in frame splicing 
of exon 7 to exon 9,  and deletion of 63 nucleotides.  The 
resulting shortened mRNA translated into a truncated pro- 
tein with a 21 amino acid deletion (residues 260-280) within 
the SH3 domain and the loop joining SH3 and SH2 of the 
BTK protein (Fig. 2 C). This prediction was confirmed by 
sequence analysis of cDNA and by Western blot analysis of 
the BTK protein. 
The availability of three generations from this family for 
study allowed us to combine RFLP and DNA techniques 
to identify the X chromosome with the mutation respon- 
sible for XLA in this family. The finding that II-6 has in- 
herited the same haplotype (A, B) as her carrier sister (II-1), 
without showing the g --* a mutation in the amplification 
mutagenesis  experiments  (not  shown)  suggests  that  the 
genomic point mutation most likely originated in the germ- 
line of I-1 or I-2. 
The SH3 domain is a small molecular domain present in 
a large number of proteins  involved in signal transduction 
and membrane-cytoskeletal  interactions. Whereas the func- 
tion  of the  SH3  domain remains  unclear,  recent reports 
provided  some important insights.  Two-hybrid  expression 
cloning was used to identify the SH3 binding protein-1 and 
to characterize a minimal proline-rich motif  within this pro- 
tein responsible for SH3 binding (18, 19). More recently, a 
large number of SH3 binding proteins have been identified 
(reviewed in 47). The critical function of SH3 domains may 
be the targeting of signaling molecules to specific subcellular 
locations (48). This would likely allow secondary  protein-pro- 
tein interactions to occur and provide specificity  in signal trans- 
duction. The biologic importance of SH3 is exemplified by 
the reported anatomic abnormalities observed in Caenorhab- 
ditis elegans caused by mutations within SH3 of sere-5, a cell 
signaling gene involved  in vulval development and in sex myo- 
blast migration (49). 
The presence of a functional SH3 domain is essential for 
the enzymatic activity of tyrosine kinases. SH3 is often ac- 
companied by another modular domain, SH2, that binds phos- 
photyrosine. The crystal structure has now been determined 
for several SH3 domains  (21-26) which form a compact/3 
barrel composed of two/3 sheets, each formed in turn by 
a series of two or three/3 strands (21). The conserved aliphatic 
and aromatic residues form a hydrophilic binding pocket on the molecular surface predicted to be the binding site for target 
proteins. In the BTK of the XLA patients described, the most 
COOH-terminal of the two exons forming the SH3 domain 
is deleted. The resulting loss of 21 amino acids, most of which 
are highly conserved within the BTK and Src families,  is 
predicted to remove two of the five ~ strands, one from each 
of the two ~  sheets,  forming the SH3 domain B barrel. In 
addition, at least three residues (equivalent to Tyr-131, Ash- 
135, Tyr-136 of c-Src), predicted to reside within the binding 
pocket of c-Src, are lost (21). As our modeling studies sug- 
gest, the deletion of part of SH3 may cause a significant al- 
teration in the folding of the mutant SH3 domain, which 
could have a dramatic effect on BTK SH3 function. Binding 
studies with this and other mutated BTK SH3 domains may 
allow identification of molecules which interact with BTK. 
In BTK, SH3 is 5' of SH2 and there are only few residues 
between them. Deletion of the COOH-terminal part of SH3 
and the connecting amino acids could change their spatial 
relationship. Our modeling suggests that this is not the case, 
since the distances between the termini are very similar in 
the wild-type and in the mutated BTK SH3. Thus, it is pos- 
sible that the mutant protein has an overall  structure that 
is very similar to the wild type differing only by the confor- 
mation of the SH3 domain and its connection to SH2. This 
is supported by the enzymatic activity of the mutant BTK 
indicating that at least the catalytic domain is properly folded. 
Src is negatively regulated by phosphorylation of Tyr-527 
in its COOH terminus and binding of this phosphotyrosine 
residue to the SH2 domain. The SH3 domain may contribute 
to  the maintenance of an inactive folded Src molecule by 
stabilizing the SH2 COOH-terminal interaction (50). Dele- 
tion of the SH3 domain of c-Src results in marked increase 
in auto- and transkimse activity and an increase in transforming 
potential (51-53). In contrast, the normal level of auto- and 
transkinase activity in the patients described here suggests 
that similar SH3 mutations in BTK are not upactivating and 
also are unlikely to result in an increase in transforming poten- 
tial.  The lack of an equivalent COOH-terminal tyrosine in 
BTK further suggests that BTK is likely to be regulated in 
alternative ways. Determination of regulatory mechanisms 
of BTK will be important for understanding its overall func- 
tion and its role in B cell development. 
Although the SH3 deletion described here does not inter- 
fere with ATP binding and protein kinase activity, the affected 
patients from this family have, nevertheless, a severe B cell 
defect characteristic for XLA. Similar to other cytoplasmic 
tyrosine kinases, BTK is likely to be involved in signal trans- 
duction through interaction with a variety of substrates in- 
volved in pathways modulating pre-B and B cell growth, 
differentiation, and mature cell function. We postulate that 
the deletion of 21 amino acids within the BTK SH3 domain 
alters the protein structure so that it disturbs interaction with 
one or more crucial SH3 binding proteins. This is likely to 
interrupt the cytoplasmic signal transduction process required 
for B cell differentiation. 
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